Pulmonart: Docetaxel - Non-Small Cell Lung Cancer (NSCLC)

NCT00174772 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

72

Enrollment

INDUSTRY

Sponsor class

Conditions

Lung Neoplasms

Interventions

DRUG: docetaxel and cisplatin followed by concurrent chemoradiotherapy with docetaxel and cisplatin + radiotherapy
DRUG: docetaxel and cisplatin + radiotherapy followed by docetaxel and cisplatin

Sponsor

Sanofi